PR Newswire
LAS VEGAS, Feb. 26, 2026
The chondrosarcoma market is anticipated to increase during the forecast period (2026-2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies such as Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others, and global healthcare spending, reports DelveInsight.
LAS VEGAS, Feb. 26, 2026 /PRNewswire/ — Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, chondrosarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Chondrosarcoma Market Summary
- The total chondrosarcoma treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounts for the largest market size of chondrosarcoma, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
- There were approximately 1,400 incident cases of chondrosarcoma in the US in 2025.
- Leading chondrosarcoma companies, such as Servier, Inhibrx Biosciences (Inhibrx Biosciences), Eli Lilly (NYSE: LLY), and others, are developing new chondrosarcoma treatment drugs that can be available in the chondrosarcoma market in the coming years.
- The promising chondrosarcoma therapies in clinical trials include TIBSOVO, Ozekibart, LY3410738, and others.
Discover chondrosarcoma treatment market trends and opportunities @ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Chondrosarcoma Market
- Rising Incidence of Chondrosarcoma: The global incidence of bone and joint cancers, including chondrosarcoma, is increasing, partly due to better diagnosis and aging populations. Chondrosarcoma accounts for a significant portion of primary bone tumors, especially in adults aged 40-70 years. There were approximately 1,400 incident cases of chondrosarcoma in the US in 2024.
- Emerging Role of INBRX-109 in Unresectable Conventional Chondrosarcoma: INBRX-109, the lead asset in the emerging landscape, could offer a new treatment option for patients with unresectable conventional chondrosarcoma.
- Launch of Emerging Chondrosarcoma Drugs: The dynamics of the chondrosarcoma market are expected to change in the coming years with the launch of emerging therapies, including Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others.
Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, noted that the chondrosarcoma treatment landscape is expected to undergo significant changes over the 2025-2034 forecast period. However, further investigation is crucial for this patient population, given the severe impact of chondrosarcoma on their quality of life and life expectancy.
Chondrosarcoma Market Analysis
- The treatment of chondrosarcoma generally includes surgery, chemotherapy, and/or radiation therapy, with the specific approach depending on the cancer’s stage and resectability.
- Despite chemotherapy being listed in updated NCCN guidelines, most chondrosarcomas, especially the conventional subtype, show poor responsiveness, and no systemic standard of care is established.
- Metastatic conventional chondrosarcoma remains a major therapeutic challenge because of its inherent resistance to both chemotherapy and radiotherapy.
- Currently, there is no approved therapy specifically for chondrosarcoma, underscoring a significant unmet need for effective treatments for this rare and aggressive cancer.
- The emerging therapeutic pipeline is limited, with investigational agents such as TIBSOVO (Servier), Ozekibart/INBRX-109 (Inhibrx Biosciences), LY3410738 (Eli Lilly), and others, undergoing clinical evaluation.
Chondrosarcoma Competitive Landscape
The clinical trial landscape for chondrosarcoma is constrained. Some of the potential products in the pipeline include Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others.
Servier’s TIBSOVO is a small-molecule inhibitor that blocks the mutant IDH1 enzyme. It is approved for use in Acute Myeloid Leukemia (AML), relapsed or refractory Myelodysplastic Syndromes (MDS), and in locally advanced or metastatic cholangiocarcinoma.
A Phase III study (NCT06127407) is now underway in adults (18+) with locally advanced or metastatic conventional chondrosarcoma carrying an IDH1 mutation. Eligible participants may be either treatment-naïve or have received one previous systemic therapy. Primary completion is anticipated in February 2028.
Inhibrx Biosciences’ Ozekibart (INBRX-109) is a tetravalent agonist that targets human Death Receptor 5 (DR5) to induce tumor-selective programmed cell death. Built using Inhibrx’s single-domain antibody platform, it is engineered to optimize both agonistic activity and safety. DR5 is a receptor for TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand). The US FDA has granted Fast Track Designation to INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma. A Phase II trial of ozekibart (NCT04950075) is currently recruiting patients with unresectable or metastatic conventional chondrosarcoma, according to ClinicalTrials.gov.
The anticipated launch of these emerging therapies are poised to transform the chondrosarcoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chondrosarcoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about new drugs in clinical trials for chondrosarcoma @ Chondrosarcoma Drugs Market
Recent Developments in the Chondrosarcoma Market
- In November 2025, Inhibrx Biosciences presented topline Phase II results for ozekibart (INBRX-109) in conventional chondrosarcoma at the 21st Annual Industry/Academia Precision Oncology & RadMed Symposium.
- In October 2025, Inhibrx Biosciences announced the positive topline results from the registrational ChonDRAgon study investigating ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Inhibrx is planning to file a Biologics License Application (BLA) in Q2 of 2026.
What is Chondrosarcoma?
Chondrosarcoma is a type of cancer that develops in the cartilage, the flexible tissue that cushions joints and helps form the skeleton. It most commonly affects the bones of the pelvis, hip, and shoulder, but it can occur in any cartilage-bearing area of the body. Unlike some other bone cancers, chondrosarcoma typically grows slowly; however, certain aggressive forms can metastasize to other parts of the body. Symptoms often include persistent pain, swelling, or a noticeable lump near the affected bone. Treatment usually focuses on surgery to remove the tumor, as chondrosarcoma is often resistant to chemotherapy and radiation.
Chondrosarcoma Epidemiology Segmentation
The chondrosarcoma epidemiology section provides insights into the historical and current chondrosarcoma patient pool and forecasted trends for the leading markets. Around 75% of conventional chondrosarcoma cases in the US in 2025 were localized, while the remaining cases were metastatic.
The chondrosarcoma treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Incident Cases of Chondrosarcoma
- Total Incident Cases of Primary Chondrosarcoma
- Grade-specific Incident Cases of Chondrosarcoma
- Mutation-specific Incident Cases of Chondrosarcoma
- Stage-specific Incident Cases of Conventional Chondrosarcoma
Chondrosarcoma Market Forecast Report Metrics
Details
Study Period
2022-2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chondrosarcoma Epidemiology Segmentation Total Incident Cases of Chondrosarcoma, Total Incident Cases of Primary Chondrosarcoma, Grade-specific Incident Cases of
Chondrosarcoma, Mutation-specific Incident Cases of Chondrosarcoma, Stage-specific Incident Cases of Conventional
Chondrosarcoma
Key Chondrosarcoma Companies
Servier, Inhibrx Biosciences (Inhibrx Biosciences), Eli Lilly (NYSE: LLY), and others
Key Chondrosarcoma Therapies
TIBSOVO, Ozekibart, LY3410738, and others
Scope of the
Chondrosarcoma
Market Report
- Therapeutic Assessment: Chondrosarcoma current marketed and emerging therapies
- Chondrosarcoma Market Dynamics: Key Market Forecast Assumptions of Emerging Chondrosarcoma Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Chondrosarcoma Market Access and Reimbursement
Download the report to understand top companies in chondrosarcoma market @ Chondrosarcoma Market Forecast
Table of Contents
1
Chondrosarcoma Market Key Insights
2
Chondrosarcoma Market Report Introduction
3
Executive Summary
4
Key Events
5
Chondrosarcoma Market Overview at a Glance
5.1 Emerging Therapies Analysis (By Phase, RoA, and Molecule Type)
5.2 Market Share (%) Distribution of Metastatic Conventional
Chondrosarcoma in 2025
5.3 Market Share (%) Distribution of Metastatic Conventional
Chondrosarcoma in 2036
6
Epidemiology and Market Forecast Methodology
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Classification
7.5
Risk Factors
7.6
Pathophysiology of Metastatic Conventional Chondrosarcoma
7.7
Diagnosis
7.8
Treatment and Guidelines
8 Epidemiology and Patient Population of Chondrosarcoma in 7MM
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3
Total Incident Cases of Chondrosarcoma in the 7MM
8.4
The United States
8.4.1 Total Incident Cases of Chondrosarcoma in the United States
8.4.2 Total Incident Cases of Primary Chondrosarcoma in the United States
8.4.3 Grade-specific Incident Cases of Chondrosarcoma in the United States
8.4.4 Mutation-specific Incident Cases of Chondrosarcoma in the United
States
8.4.5 Stage-specific Incident Cases of Chondrosarcoma in the United States
8.5
EU4 and the UK
8.6
Japan
9
Chondrosarcoma Patient Journey
10
Emerging Chondrosarcoma Therapies
10.1
Key Cross Competition
10.2
INBRX-109: Inhibrx Biosciences
10.2.1
Product Description
10.2.2
Other Developmental Activities
10.2.3.1
Clinical Trials Information
10.2.4
Safety and Efficacy
10.2.5
Analyst Views
10.3
TIBSOVO (ivosidenib): Servier
List to be continued in the report…
11
Chondrosarcoma Market: 7MM Analysis
11.1
Key Findings
11.2
Chondrosarcoma Market Outlook
11.3
Conjoint Analysis
11.4
Key Chondrosarcoma Market Forecast Assumptions
11.5
Total Market Size of Chondrosarcoma in the 7MM
11.6 Total Market Size of Chondrosarcoma by Therapies in the 7MM
11.7
The United States Chondrosarcoma Market Size
11.7.1
Total Market Size of Chondrosarcoma in the United States
11.7.2 Market size of Chondrosarcoma by Therapies in the United States
11.8
EU4 and the UK Chondrosarcoma Market Size
11.9
Japan Chondrosarcoma Market Size
12
Key Opinion Leaders’ Views on Chondrosarcoma
13
Chondrosarcoma Market SWOT Analysis
14
Chondrosarcoma Market Unmet Needs
15
Chondrosarcoma Market Access and Reimbursement
15.1
The United States
15.2
In EU4 and the UK
15.3
Japan
15.4 Summary and Comparison of Market Access and Pricing Policy
Developments in 2025
16
Bibliography
17
Chondrosarcoma Market Report Methodology
Related Reports
Chondrosarcoma Clinical Trial Analysis
Chondrosarcoma Pipeline Insight
– 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chondrosarcoma companies, including PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co., Ltd., Hutchmed, Atlanthera, and others.
Osteosarcoma Market
Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies, including Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others.
Soft Tissue Sarcoma Market
Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key STS companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Ewing Sarcoma Market
Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including SALARIUS PHARMACEUTICALS, JAZZ PHARMACEUTICALS AND PHARMAMAR, ELI LILLY, PFIZER, BIOATLA, CELLECTAR BIOSCIENCES, SUMITOMO PHARMA ONCOLOGY, INHIBRX, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us :Shruti Thakur [email protected] +14699457679 www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chondrosarcoma-treatment-market-forecasts-robust-growth-during-the-forecast-period-20262036-as-oncology-pipeline-strengthens–delveinsight-302697879.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…